|
|
Volumn 13, Issue 1, 2012, Pages 14-15
|
|
Drivers of the cost of cancer care
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
5 AZA 2' DEOXYCYTIDINE;
ANASTROZOLE;
ANTINEOPLASTIC AGENT;
BEVACIZUMAB;
BORTEZOMIB;
CAPECITABINE;
CETUXIMAB;
CLOFARABINE;
DASATINIB;
DOCETAXEL;
DOXORUBICIN;
ERLOTINIB;
EVEROLIMUS;
EXEMESTANE;
GEMCITABINE;
GEMTUZUMAB;
IMATINIB;
IRINOTECAN;
IXABEPILONE;
LETROZOLE;
LEUPRORELIN;
NELARABINE;
PANITUMUMAB;
PEMETREXED;
PRALATREXATE;
SUNITINIB;
TAMOXIFEN;
VORINOSTAT;
CANCER CHEMOTHERAPY;
CANCER RADIOTHERAPY;
CANCER SURGERY;
COST BENEFIT ANALYSIS;
COST EFFECTIVENESS ANALYSIS;
DRUG COST;
HEALTH CARE COST;
HEALTH SERVICE;
HUMAN;
LETTER;
MALIGNANT NEOPLASTIC DISEASE;
PATIENT CARE;
PRIORITY JOURNAL;
TERMINAL CARE;
DELIVERY OF HEALTH CARE, INTEGRATED;
HEALTH CARE COSTS;
HEALTH EXPENDITURES;
HEALTH SERVICES ACCESSIBILITY;
HUMANS;
NEOPLASMS;
|
|
EID: 84855301222
PISSN: 14702045
EISSN: 14745488
Source Type: Journal
DOI: 10.1016/S1470-2045(11)70370-9 Document Type: Letter |
|
Times cited : (6)
|
|
References (4)
|
